secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-004098
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML
--------------------------------------------------------------------------------

- Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.
- Ziftomenib Phase 1: 30% CR rate among 20 NPM1-mutant AML patients at 600 mg recommended Phase 2 dose.
- Registration-directed trial KOMET-001 dosed multiple patients; 85-patient enrollment target in US and Europe.
- FDA cleared IND for KO-2806, next-generation farnesyl transferase inhibitor; Phase 1 trial expected Q3 2023.
- Bristol Myers Squibb made $25M strategic equity investment at $18.25/share; appointed member to steering committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/0000950170-23-004098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023004098/kura-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer